Discover a groundbreaking webinar delving into advancements in antibody-drug conjugates (ADCs) and related patent filings. Antibody-drug conjugates are among the most promising drug classes in oncology. The ADC research landscape is rapidly evolving, driven by advancements in antibody engineering, linker technology, payload development and diversification and more.
Rapid advancements in antibody-drug conjugates research, increasing commercial investment and expanding diversity of non-cancer disease applications are reshaping the future promise of ADCs. However, they also present challenges for innovators and drug developers seeking to understand the complex and competitive intellectual property (IP) landscape.
Join this webinar to gain insights into the latest trends in antibody-drug conjugate innovation and the complications of understanding the IP landscape in this area. The experts will highlight the critical importance of staying up to date with evolving research and development (R&D) trends and patent filings to determine freedom to operate, protect complex innovations and maximize return on investment (ROI).
Janet Sasso, Information Scientist, CAS
Janet M. Sasso earned her BS in Biology from The Ohio State University. She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She and her team have recently studied the landscape of antibody drug conjugates to provide insights into the scientific advances of the field.
Natalia Nekrasova, IP Search Analyst, CAS
Natalia Nekrasova is an IP Search Analyst with CAS IP Services who has 20 years of experience as an information professional focusing on life sciences, pharmaceuticals and biosequences. She has held prior roles in the development of specialized search and retrieval products. She holds an MS in Biochemistry from St Petersburg State University in Russia and an MS in Library and Information Science from Kent State University. She is a member of PIUG and the American Chemical Society.
Who Should Attend?
This webinar will appeal to IP and R&D professionals in:
What You Will Learn
Attendees will gain insights into:
- The evolving global research and intellectual property (IP) landscape of antibody-drug conjugates
- Unique challenges of developing antibody-drug conjugates (ADCs) therapeutics, understanding the competitive landscape and complex patent claims for related technologies
- Strategies for a comprehensive IP search to inform investment and protect innovations
- Insights into how CAS content and solutions can enable innovators and IP professionals
CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at cas.org.